ARTICLE | Clinical News
Elagolix: Phase IIb data
September 21, 2015 7:00 AM UTC
The double-blind, international Phase IIb M12-813 trial in about 567 premenopausal women with heavy menstrual bleeding associated with uterine fibroids showed that twice-daily 300 mg and once-daily 60...